At SeromYx, our research has advanced both vaccine and antibody therapeutic development. Our publications highlight innovative approaches such as high-dimensional immune profiling and Fc effector function assays. Explore our latest work to see the science behind our platform.
Featured Publication
This featured publication highlights the importance of early Fc effector function profiling in antibody therapeutic development. Explore how antibody structure and function intersect to inform safer, more effective design strategies.
Title: The importance of broadly measuring Fc mediated effector function early in the antibody development process
Authors: Crescioli, S, Jatiani, S, & Moise, L, (2025). mAbs, 17(1).
Journal: mAbs
Journal Abstract: Antibody therapeutics are rapidly evolving, with new formats and engineered designs expanding their potential across a range of diseases. A comprehensive evaluation of Fc-mediated effector functions early in development is critical to guide safe, effective therapeutic design.
Authors: Bronwyn M. Gunn, et al. Cell Host Microbe. 2018 Aug 8; 24(2): 221–233.e5. Journal: Cell Host Microbe
Authors: Erica Ollmann Saphire*, et al. Cell. 2018 Aug 9; 174(4): 938–952.e13. Journal: Cell
Authors: Barouch DH, et al. Lancet. 2018 Jul 21; 392(10143): 232–243. Journal: Lancet
Authors: Suscovich TJ, et. al. Science Translational Medicine. 2020 Jul; 12(553): eabb4757 Journal: Science Translational Medicine
Authors: Atyeo et al. Immunity (2020) Journal: Immunity
Authors: Bronwyn M. Gunn, et al. Cell Host Microbe. 2018 Aug 8; 24(2): 221–233.e5. Journal: Cell Host Microbe
